Skip to main content
TipRanks
Go Ultimate75% OFF

ALK-abello (4AJ0) Q3 2026 Earnings Report

2 Followers

DE:4AJ0 Q3 2026 EPS Results

Actual EPS
EUR 0.21
Consensus EPS
EUR 0.11
Beat/Miss
Beat by +EUR 0.10
One Year Ago EPS
EUR 0.19

DE:4AJ0 Q3 2026 Revenue Results

Actual Revenue
EUR 236.01M
Expected Revenue
EUR 235.34M
Beat/Miss
Beat by +EUR 668.95K
YoY Revenue Growth
+15.29%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/17/2026
Time
Before Open
Conference Call
Tuesday, November 17, 2026
DE:4AJ0 Upcoming Earnings

ALK-abello's next earnings date is estimated for February 9, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:4AJ0 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 17, 2026|% Change Since:-3.74%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. ALK reported broad-based revenue growth, robust tablet momentum, improved gross margin, higher profit and cash flow, successful pediatric expansion, positive ACARIZAX Phase III results in China, progress for neffy and an upgraded full-year outlook. Offsetting factors included the Q3 EBIT-margin decline, temporary wholesaler stocking, declining SCIT and SLIT drop sales, modest neffy revenue, uncertainty around Germany's rebate increase and significant cost-base growth during 2026. Highlights significantly outweighed the lowlights.

Company Guidance

For the full year, ALK confirmed revenue growth of 16% to 17% in local currencies, up from the previous 14% to 16%, and an EBIT margin around 27%, up from 26%; growth will predominantly be volume-driven, with tablet sales expected to grow by double digit across regions, children and adolescent projected to account for a higher share of sales, combined SCIT and SLIT drop sales anticipated to grow by single digits, and Anaphylaxis and other products projected to increase by low double digits with a modest contribution from neffy. Gross margin is expected to be slightly higher than last year's 67%, capacity costs are still projected to increase with the ratio to revenue largely on par with that of last year, R&D is expected to slightly exceed 10% of revenue, CapEx is projected at around DKK 400 million, and free cash flow is now expected to exceed DKK 1.1 billion; ALK said it is planning for a much more moderate increase in its cost base next year compared to 2026, expects a contribution from neffy to the numbers next year, and is in a favorable position to continue to deliver more than 10% growth in the years ahead.

  • Strong Q3 Revenue and EBIT GrowthQ3 revenue increased 15% in local currencies across all regions to DKK 1.76 million, driven by tablets. EBIT increased 9% to DKK 469 million. The EBIT margin was 27%, compared with 28% last year, while the nine-month margin remained unchanged at 28%.
  • Record-Level Tablet PerformanceGlobal tablet sales increased 35% to DKK 999 million, representing 57% of group revenue and remaining close to the DKK 1 billion level seen in Q1 and Q2. Growth was increasingly driven by the pediatric rollout.
  • Broad-Based Regional GrowthEurope revenue increased 18% in local currencies, North America revenue increased 8% to DKK 270 million, and international-market revenue increased 6% to DKK 248 million. All three sales regions grew in Q3.
  • European Tablet Growth and Pediatric MomentumEuropean tablet sales grew 33%, mainly reflecting volume growth linked to patient inflows during the 2025 and 2026 initiation season. All tablet brands grew by double digits, led by ITULAZAX, while pediatric launches increasingly contributed to growth and treatment adherence showed signs of improvement in the child and adolescent segment.
  • Positive Initiation Season TrendsManagement described the tree tablet ITULAZAX initiation season as very solid, particularly for birch and other relevant tree varieties. The grass tablet GRAZAX initiation season was described as fair and at a reasonable, more normal level, while ACARIZAX continued to develop as a year-round treatment.
  • North American Tablet GrowthNorth American tablet sales increased 32%, mostly driven by Canada, which continued to see sustained high growth helped by the pediatric rollout. The U.S. also delivered double-digit growth, supported by increased promotional efforts.
  • International Tablet ExpansionTablet revenue in international markets increased 47%, following product shipments and sales royalties from Japan and growth in most smaller Southeast Asian markets. Japan's in-market sales growth accelerated, particularly for CEDARCURE, driven by stronger active pharmaceutical ingredient supply from Torii's new manufacturing facility.
  • Positive ACARIZAX Phase III Results in ChinaThe Phase III trial for ACARIZAX in China met its primary objective, with efficacy and safety consistent with more than 10 years of clinical data. The treatment difference favored ACARIZAX over placebo with a relative difference of 19.1%, and treatment compliance was high. ALK and GenSci plan to file for regulatory approval as soon as possible in the first half of 2027.
  • Expanded Catalent Partnership and CapacityThe expanded Catalent partnership secures long-term access to Zydis tablet technology for all ALK allergen products and increases prioritized tablet capacity by 300 million tablets, or approximately 40%, to 1.1 billion tablets annually from the early 2030s. ALK expects to make payments of approximately DKK 500 million over three years, capitalized on the balance sheet and amortized over the contract.
  • Progress in neffy CommercializationDirect neffy sales in Europe and Canada increased approximately sixfold in Q3. EURneffy sales in Europe increased approximately 250%, mainly in Germany, while the Canadian launch of the 2-milligram version and the German launch of the 1-milligram version received encouraging initial feedback. The Canadian Schedule II classification also enables neffy to be obtained without a prescription in areas where one was previously required.
  • Expansion of neffy PartnershipsALK signed a partnership with Zuellig Pharma to bring neffy to selected Southeast Asian markets, including Singapore, Thailand, the Philippines, Malaysia, Indonesia and Vietnam, subject to regulatory approval.
  • Progress Across Pediatric ProgramsBy the end of Q3, the house dust mite tablet was approved for pediatric use in 36 countries and launched in 24, while ITULAZAX was approved for children and adolescents in 20 countries and launched in 14. Management said key performance indicators remained strong and pediatric prescriber recruitment continued to progress.
  • Advancement of Food Allergy and Pipeline ProgramsPreparations progressed for the pivotal Phase III trial of ALK's peanut tablet, with the clinical trial application submitted to the U.S. FDA and feedback pending. ALK014 continued progressing toward clinical development in 2027, and interim Phase IIb data for neffy in acute flares of chronic spontaneous urticaria remained expected in the first quarter of 2027.
  • Improved Nine-Month Financial PerformanceNine-month revenue increased 17% in local currencies to DKK 5.3 billion, with reported growth negatively affected by 1 percentage point from exchange rates, mainly due to the weaker U.S. dollar. Gross profit was DKK 3.6 billion and gross margin increased to 68% from 67%, driven by higher sales volumes, production efficiencies and a higher proportion of direct sales.
  • Higher Operating Profit and Cash FlowNine-month operating profit increased 16% in local currencies to almost DKK 1.5 billion, while net profit increased to DKK 1.1 billion. Free cash flow increased to DKK 1.19 billion from DKK 836 million, and Q3 free cash flow was DKK 303 million. Net debt-to-EBITDA remained negative at 0.7.
  • Upgraded and Confirmed Full-Year OutlookALK confirmed its upgraded full-year outlook, expecting revenue growth of 16% to 17% in local currencies, up from the previous 14% to 16%. The expected EBIT margin increased to around 27% from 26%, and free cash flow is now expected to exceed DKK 1.1 billion. Tablet sales are expected to grow by double digit across regions.
  • Potential Danish Tax BenefitManagement said the proposed Danish corporate tax-rate reduction from 22% to 19%, if fully implemented, could reduce ALK's effective tax rate from approximately 24% to 25% to around 21%, because a significant portion of the company's profit is taxed in Denmark.
  • Continued Market-Share OpportunityManagement stated that ALK continues to win market share across most markets and currently holds approximately the 50% mark, plus or minus. The company expects opportunities to continue winning market share and to outperform overall global market growth.
  • Positive Outlook for Anaphylaxis PortfolioManagement described the anaphylaxis portfolio outlook as positive, with Jext benefiting from a stronger supply position and neffy positioned for patient conversion and market expansion. The company said double-digit growth for the anaphylaxis portfolio could be foreseeable going forward.

DE:4AJ0 Earnings History

DE:4AJ0 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 09, 20272026 (Q4)0.23-0.16――
Nov 17, 20262026 (Q3)0.110.210.1914.29% (+0.03)
Aug 20, 20262026 (Q2)0.200.200.1625.00% (+0.04)
May 04, 20262026 (Q1)0.230.270.2125.00% (+0.05)
Feb 20, 20262025 (Q4)0.170.160.1150.00% (+0.05)
Nov 12, 20252025 (Q3)0.130.190.1340.00% (+0.05)
Aug 21, 20252025 (Q2)0.170.160.1233.33% (+0.04)
May 06, 20252025 (Q1)0.180.210.1545.45% (+0.07)
Feb 19, 20252024 (Q4)0.130.110.0920.30% (+0.02)
Nov 14, 20242024 (Q3)0.110.130.07100.00% (+0.07)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed